BeOne Medicines Ltd.
百濟神州有限公司
(a corporation incorporated under the laws of Switzerland)
(Stock Code: 06160)

NOTICE OF AUDIT COMMITTEE ACTION

BeOne Medicines Ltd. (the "**Company**") hereby announces that the audit committee of the board of directors (the "**Board**") will, on August 26, 2026 (Hong Kong Time), consider and approve, inter alia, the interim results of the Company and its subsidiaries for six months ended June 30, 2026 and its publication in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**"). The Company previously announced its interim results for the three and six months ended June 30, 2026 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (the "**SEC**") on August 5, 2026. **The interim results to be published by the Company in accordance with the Hong Kong Listing Rules are the same as previously announced by the Company and filed with the SEC, except for specific additional information required by the Hong Kong Listing Rules, together with a reconciliation of the Company's interim results from U.S. Generally Accepted Accounting Principles to International Financial Reporting Standards.**

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, August 14, 2026

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.